In high-risk T2DM, canagliflozin reduced CV events regardless of baseline renal function. (2019)
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.7326/acpj201902190-015
PubMed Identifier: 30776804
Publication URI: http://europepmc.org/abstract/MED/30776804
Type: Journal Article/Review
Volume: 170
Parent Publication: Annals of internal medicine
Issue: 4
ISSN: 0003-4819